On July 6, InnoCare Pharma (09969.HK) rose 6.65% in regular trading, trading at HK$14.03/share, with turnover of HK$72.80 million.

On the news front, InnoCare Pharma announced that its self-developed CDH17-targeting novel ADC innovative drug ICP-B208 has completed first patient dosing, officially marking the drug's entry into the clinical stage. Built on InnoCare's proprietary ADC technology platform, ICP-B208 consists of a humanized anti-CDH17 antibody conjugated via a protease-cleavable linker to a proprietary potent payload, designed to precisely target tumor cells while minimizing off-target effects.

The milestone adds to a series of recent pipeline advances for the company, including the acceptance of a new drug application for orelabrutinib in primary immune thrombocytopenia, Australian approval for orelabrutinib in relapsed/refractory mantle cell lymphoma, and the first subject enrollment in the Phase 1 trial of oral IL-17AA/AF inhibitor ICP-054. The broader Biotechnology sector also saw gains, with REMEGEN up 4.95%, INNOVENT BIO up 5.01%, and SKB BIO up 4.11%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)